Prot #213304: Expanded Access Program for Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody

Project: Research project

Project Details

StatusFinished
Effective start/end date3/11/20 → 3/11/23

Funding

  • Quintiles, Inc. (Prot #213304 // Prot #213304)
  • GlaxoSmithKline LLC (Prot #213304 // Prot #213304)